The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Open accessAbstract
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths. RESULTS: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects. CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vemurafenib, a selective oral inhibitor of the BRAF V600 kinase, achieved an approximately 50% response and improved survival among metastatic melanoma patients with the BRAF V600E mutation [97].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [97]
In the citing paper
“Maturation of survival data also increased the ESMO-MCBS score of vemurafenib in the treatment of metastatic melanoma [116, 117] from ESMO-MCBS 3 based on PFS to 4, based on OS.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Flagged first, then by citations
Research works printed but not linked: 1
- Kumar R, 2003, Clin Cancer Res, 9, 3362
Cited by
Sorted by citations
Items 701–800 of 1,053
Ascierto, P. A., Kalos, M. D., Schaer, D., Callahan, M. K., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2982 · Cited by 141
Self-citationFGFR3-TACC3 fusion in solid tumors: mini review
Costa, R. L. B., Carneiro, B. A., Taxter, T., Tavora, F. A., Kalyan, A., Pai, S. G., Chae, Y. K., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.10482 · Cited by 141
Targeted drug delivery to melanoma
Liu, Q., Das, M., Liu, Y., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.016 · Cited by 139
Advances in drug discovery based on network pharmacology and omics technology
Liu, Y., Zhang, S., Liu, K., Hu, X., & Gu, X. (2024) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2024.12.002 · Cited by 142
25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
Fabbro, D. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095489 · Cited by 141
Hypoxia Contributes to Melanoma Heterogeneity by Triggering HIF1α-Dependent Phenotype Switching
Widmer, D. S., Hoek, K. S., Cheng, P. F., Eichhoff, O. M., Biedermann, T., Raaijmakers, M. I. G., Hemmi, S., Dummer, R., & Levesque, M. P. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.115 · Cited by 147
Self-citationAnderson, S., Bloom, K. J., Vallera, D. U., Rueschoff, J., Meldrum, C. J., Schilling, R., Kovach, B., Lee, J. R.-J., Ochoa, P., Langland, R., et al. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0505-oa · Cited by 139
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
c-Met as a Target for Personalized Therapy
Garajová, I., Giovannetti, E., Biasco, G., & Peters, G. J. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30534 · Cited by 141
Lind, A. P., & Anderson, P. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219774 · Cited by 141
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance
Flach, E. H., Rebecca, V. W., Herlyn, M., Smalley, K. S. M., & Anderson, A. R. A. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200421k · Cited by 142
Haroche, J., Arnaud, L., Aubart, F. C., Hervier, B., Charlotte, F., Emile, J., & Amoura, Z. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-014-0412-0 · Cited by 136
RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
Yajima, I., Kumasaka, M. Y., Thang, N. D., Goto, Y., Takeda, K., Yamanoshita, O., Iida, M., Ohgami, N., Tamura, H., Kawamoto, Y., et al. (2011) · Dermatology Research and Practice · doi:10.1155/2012/354191 · Cited by 141
American Society of Clinical Oncology 2013 Top Five List in Oncology
Schnipper, L. E., Lyman, G. H., Blayney, D. W., Hoverman, J. R., Raghavan, D., Wollins, D. S., & Schilsky, R. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3943 · Cited by 134
Malapelle, U., de-las-Casas, C. M., Rocco, D., Garzón, M., Pisapia, P., Jordana‐Ariza, N., Russo, M., Sgariglia, R., Luca, C. D., Pepe, F., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.8 · Cited by 136
Drug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135
Takashima, A., & Faller, D. V. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.764990 · Cited by 140
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Pérez-Mancera, P. A., Rashid, M., Iorio, F., Alifrangis, C., Arends, M. J., Bosenberg, M., Bollag, G. E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418163112 · Cited by 139
Catalanotti, F., Solit, D. B., Pulitzer, M. P., Berger, M. F., Scott, S. N., Iyriboz, T. A., Lacouture, M. E., Panageas, K. S., Wolchok, J. D., Carvajal, R. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3476 · Cited by 135
Self-citationMorris, V., Overman, M. J., Jiang, Z.-Q., Garrett, C., Agarwal, S., Eng, C., Kee, B., Fogelman, D., Dasari, A., Wolff, R., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.001 · Cited by 132
Evolving health care through personal genomics
Rehm, H. L. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.162 · Cited by 142
Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer
Zhang, P., Kawakami, H., Liu, W., Zeng, X., Strebhardt, K., Tao, K., Huang, S., & Sinicrope, F. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0404 · Cited by 133
Prevalence of class I–III BRAF mutations among 114,662 cancer patients in a large genomic database
Owsley, J., Stein, M. K., Porter, J., In, G. K., Salem, M. E., O'Day, S. J., Elliott, A., Poorman, K. A., Gibney, G. T., & Vanderwalde, A. M. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220959657 · Cited by 139
Self-citationAcquired resistance in cancer: towards targeted therapeutic strategies
Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 151
“Mechanistic preclinical studies and analyses of clinical specimens have indicated that resistance is often due to mutations, loss of the target or use of alternative pathways to enable survival and drive proliferation in spite of selective targeting 71,72 .”
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
Niezgoda, A., Niezgoda, P., & Czajkowski, R. (2015) · BioMed Research International · doi:10.1155/2015/851387 · Cited by 138
Clancy, C., Burke, J. P., Kalady, M. F., & Coffey, J. C. (2013) · Colorectal Disease · doi:10.1111/codi.12427 · Cited by 133
Next-generation sequencing technologies: breaking the sound barrier of human genetics
Bahassi, E. M., & Stambrook, P. J. (2014) · Mutagenesis · doi:10.1093/mutage/geu031 · Cited by 138
Goeppert, B. F., Frauenschuh, L., Renner, M., Roessler, S. K., Stenzinger, A., Klauschen, F., Warth, A., Vogel, M. N., Mehrabi, A., Hafezi, M., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.206 · Cited by 133
Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells
Quigley, D. A., & Kristensen, V. N. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.003 · Cited by 132
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
Urner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Parseval, L. M., Dummer, R., & Goldinger, S. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu169 · Cited by 135
Self-citationVemurafenib resistance reprograms melanoma cells towards glutamine dependence
Hernandez-Davies, J. E., Tran, T. Q., Reid, M. A., Rosales, K. R., Lowman, X. H., Pan, M., Moriceau, G., Yang, Y., Wu, J., Lo, R. S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0581-2 · Cited by 131
Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
Chen, D., Davis-Yadley, A. H., Huang, P., Husain, K. M., Centeno, B. A., Permuth‐Wey, J., Pimiento, J. M., & Malafa, M. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133562 · Cited by 132
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., López-Coral, A., Xu, X., Zhang, G., Azuma, R., Liu, Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1554 · Cited by 134
Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
Gammons, M. V. R., Lucas, R., Dean, R., Coupland, S. E., Oltean, S., & Bates, D. O. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.342 · Cited by 138
Objective assessment of cancer genes for drug discovery
Patel, M. N., Halling‐Brown, M., Tym, J. E., Workman, P., & Al‐Lazikani, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3913 · Cited by 133
Melanoma: From Melanocyte to Genetic Alterations and Clinical Options
Bertolotto, C. (2013) · Scientifica · doi:10.1155/2013/635203 · Cited by 152
Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv139 · Cited by 132
Self-citationCTLA ‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
Camacho, L. H. (2015) · Cancer Medicine · doi:10.1002/cam4.371 · Cited by 136
Targeting RAS -mutant Cancers: Is ERK the Key?
Ryan, M. B., Der, C. J., Wang‐Gillam, A., & Cox, A. D. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 133
Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene
Fontanals-Cirera, B., Hasson, D., Vardabasso, C., Micco, R. D., Agrawal, P. K., Chowdhury, A. H., Gantz, M., de Pablos-Aragoneses, A., Morgenstern, A., Wu, P., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.004 · Cited by 134
Acute Respiratory Distress Syndrome Phenotypes
Reilly, J. P., Calfee, C. S., & Christie, J. D. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1684049 · Cited by 136
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer
Foppen, M. H. G., Donia, M., Svane, I. M., & Haanen, J. B. A. G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.018 · Cited by 133
Self-citationClinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
Litvak, A. M., Paik, P. K., Woo, K. M., Sima, C. S., Hellmann, M. D., Arcila, M. E., Ladanyi, M., Rudin, C. M., Kris, M. G., & Riely, G. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000344 · Cited by 132
Phosphorylation of BRAF by AMPK Impairs BRAF-KSR1 Association and Cell Proliferation
Shen, C., Yuan, P., Pérez‐Lorenzo, R., Zhang, Y., Lee, S. X., Ou, Y., Asara, J. M., Cantley, L. C., & Zheng, B. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.044 · Cited by 138
Molecular Pathways: Dysregulated Glutamatergic Signaling Pathways in Cancer
Prickett, T. D., & Samuels, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1217 · Cited by 131
Dadu, R., Shah, K. B., Busaidy, N. L., Waguespack, S. G., Habra, M. A., Ying, A. K., Hu, M. I.-N., Bassett, R. L., Jiménez, C., Sherman, S. I., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2246 · Cited by 131
Interferons and the immunogenic effects of cancer therapy
Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130
Johnson, G. L., Stuhlmiller, T. J., Angus, S. P., Zawistowski, J. S., & Graves, L. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1081 · Cited by 129
Mostert, B., Jiang, Y., Sieuwerts, A. M., Wang, H., Vries, J. B., Biermann, K., Kraan, J., Lalmahomed, Z. S., van Galen, A., de Weerd, V., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27987 · Cited by 133
Romano, E., Pradervand, S., Paillusson, A., Weber, J., Harshman, K., Muehlethaler, K., Speiser, D. E., Peters, S., Rimoldi, D., & Michielin, O. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0661 · Cited by 130
Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update
Harmon, C. M., & Brown, N. A. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0199-ra · Cited by 132
ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
Richard, G., Dalle, S., Monet, M., Plaschka, M., Boespflug, A. M., Pommier, R. M., de la Fouchardière, A., Perier‐Muzet, M., Depaepe, L., Barnault, R., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505971 · Cited by 140
Variant classification in precision oncology
Leichsenring, J., Horak, P., Kreutzfeldt, S., Heining, C., Christopoulos, P., Volckmar, A., Neumann, O., Kirchner, M., Ploeger, C., Budczies, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32358 · Cited by 131
Aloia, A., Müllhaupt, D., Chabbert, C. D., Eberhart, T., Flückiger-Mangual, S., Vukolic, A., Eichhoff, O., Irmisch, A., Alexander, L. T., Scibona, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0253 · Cited by 130
“BRAFis alone or in combination with MEKis have shown clinical efficacy inpatientswithBRAF-mutatedmetastaticmelanoma (7, 8).”
BackgroundSelf-citationTrial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 132
Self-citationCutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
Reyes-Habito, C. M., & Roh, E. K. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.04.013 · Cited by 129
Bogaerts, J., Sydes, M. R., Keat, N., McConnell, A., Benson, A. B., Ho, A. L., Roth, A. D., Fortpied, C., Eng, C., Peckitt, C., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.10.027 · Cited by 131
Fu, F., Nowak, M. A., & Bonhoeffer, S. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004142 · Cited by 129
Sánchez‐Laorden, B. L., Virós, A., Girotti, M. R., Pedersen, M., Saturno, G., Zambon, A., Niculescu‐Duvaz, D., Turajlic, S., Hayes, A. J., Gore, M. E., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004815 · Cited by 131
Self-citationBrainstem Ganglioglioma Successfully Treated With Vemurafenib
Rush, S. Z., Foreman, N. K., & Liu, A. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1568 · Cited by 129
Sun, X., Bao, J., & Shao, Y. (2016) · Scientific Reports · doi:10.1038/srep22498 · Cited by 133
CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer
Vaghari‐Tabari, M., Hassanpour, P., Sadeghsoltani, F., Malakoti, F., Alemi, F., Qujeq, D., Asemi, Z., & Yousefi, B. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00348-2 · Cited by 137
“EGFR in lung cancer [13], BRAF in melanoma [14], BCR–ABL fusion in chronic myeloid leukemia [15], HER2 in breast cancer [16], and FGFR in different types of cancer [17] are among the most important targets, and some well-known anticancer drugs have been designed”
BackgroundThe role of the PI3K pathway in colorectal cancer
Papadatos-Pastos, D., Rabbie, R., Ross, P., & Sarker, D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.006 · Cited by 126
Primary Melanocytic Tumors of the Central Nervous System: a Review with Focus on Molecular Aspects
Küsters-Vandevelde, H., Küsters, B., Grunsven, A. V. E. V. E.-V., Groenen, P. J. T. A., Wesseling, P., & Blokx, W. (2015) · Brain Pathology · doi:10.1111/bpa.12241 · Cited by 113
BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
Nguyen‐Ngoc, T., Bouchaab, H., Adjei, A. A., & Peters, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000644 · Cited by 135
Mucosal Melanoma: Epidemiology, Biology and Treatment
Spencer, K. R., & Mehnert, J. M. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_13 · Cited by 134
ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition
Wang, B., Krall, E. B., Aguirre, A. J., Kim, M., Widlund, H. R., Doshi, M. B., Sicińska, E., Sulahian, R., Goodale, A. B., Cowley, G. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.031 · Cited by 129
Effect Sizes of Somatic Mutations in Cancer
Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy168 · Cited by 128
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers
Subbiah, V., Puzanov, I. J., Blay, J., Chau, I., Lockhart, A. C., Raje, N. S., Wolf, J., Baselga, J. M., Meric‐Bernstam, F., Roszik, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1265 · Cited by 129
“Specifically, VE-BASKET was intended to explore the efficacy of vemurafenib in patients with any BRAFV600 mutation– positive cancers other than melanoma, papillary thyroid cancer, and hairy cell leukemia, cancers for which efficacy had been previously defined in traditional tumorspecific studies (6, 11, 12).”
BackgroundAntitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Nakamura, A., Arita, T., Tsuchiya, S., Donelan, J., Chouitar, J., Carideo, E. G., Galvin, K. M., Okaniwa, M., Ishikawa, T., & Yoshida, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1825 · Cited by 124
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
Holderfield, M. T., Nagel, T., & Stuart, D. D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.139 · Cited by 128
Durmuş, S., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3003144 · Cited by 127
Zucker, S. N., Zirnheld, J. L., Bagati, A., DiSanto, T. M., Soye, B. J. D., Wawrzyniak, J. A., Etemadi, K., Nikiforov, M. A., & Berezney, R. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21787 · Cited by 131
Seghers, A. C., Wilgenhof, S., Lebbé, C., & Neyns, B. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e3283541541 · Cited by 127
Ascierto, P. A., Simeone, E., Giannarelli, D., Grimaldi, A. M., Romano, A., & Mozzillo, N. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-107 · Cited by 131
Self-citationMelanoma as a model tumour for immuno-oncology
Maio, M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds257 · Cited by 127
Self-citationSchmidt, K. T., Chau, C. H., Price, D. K., & Figg, W. D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.765 · Cited by 129
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Millet, A., Martin, A. R., Ronco, C., Rocchi, S., & Benhida, R. (2016) · Medicinal Research Reviews · doi:10.1002/med.21404 · Cited by 135
Hong, X., Sullivan, R. J., Kalinich, M., Kwan, T. T., Giobbie‐Hurder, A., Pan, S., LiCausi, J. A., Milner, J. D., Nieman, L. T., Wittner, B. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719264115 · Cited by 129
Self-citationCombination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
“The median PFS was usually observed within 5 to 7 months (20, 23, 24).”
BackgroundClinical Analysis and Interpretation of Cancer Genome Data
Allen, E. M. V., Wagle, N., & Levy, M. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7215 · Cited by 128
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer
Wellbrock, C., & Arozarena, I. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00033 · Cited by 132
Bergamo, A., Dyson, P. J., & Sava, G. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.01.009 · Cited by 131
Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib
Tong, M., Che, N., Zhou, L., Luk, S. T.-C., Kau, P. W., Chai, S., Ngan, E., Lo, C. M., Man, K., Ding, J., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.034 · Cited by 126
“cascades, rather than specific DNA aberrations, as was described with BCR-ABL and imatinib (7) and BRAF mutations in melanoma resistant to vemurafenib (8).”
BackgroundMarzuka-Alcalá, A., & Flaherty, K. T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0997 · Cited by 128
Self-citationPéron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 132
Deregulation of cell signaling in cancer
Giancotti, F. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.005 · Cited by 133
Singh, V., Salunga, R. C., Huang, V. J., Tran, Y., Erlander, M. G., Plumlee, P., & Peterson, M. R. (2013) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2013.02.001 · Cited by 124
Targeted therapies for gastric cancer: failures and hopes from clinical trials
Apicella, M., Corso, S., & Giordano, S. (2017) · Oncotarget · doi:10.18632/oncotarget.14825 · Cited by 126
EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Miao, B., Ji, Z., Tan, L., Taylor, M., Zhang, J., Choi, H. G., Frederick, D. T., Kumar, R., Wargo, J. A., Flaherty, K. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0295 · Cited by 124
Self-citationOvercoming resistance to BRAF inhibitors
Arozarena, I., & Wellbrock, C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.09 · Cited by 131
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma
Chakraborty, B., Byemerwa, J. K., Shepherd, J., Haines, C., Baldi, R., Gong, W., Liu, W., Mukherjee, D., Artham, S., Lim, F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151347 · Cited by 131
CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
Mao, Y., Chen, H., Liang, H., Meric‐Bernstam, F., Mills, G. B., & Chen, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077945 · Cited by 123
Wong, D. J. L., Robert, L., Atefi, M. S., Lassen, A., Avarappatt, G., Cerniglia, M., Avramis, E. V., Tsoi, J., Foulad, D. S., Graeber, T. G., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-194 · Cited by 126
Self-citationTargeted therapy for melanoma: rational combinatorial approaches
Kwong, L. N., & Davies, M. A. (2013) · Oncogene · doi:10.1038/onc.2013.34 · Cited by 123
Cherny, N. I., de Vries, E. G. E., Dafni, U. G., Garrett-Mayer, E. S., McKernin, S. E., Piccart, M. J., Latino, N. J., Douillard, J.-Y., Schnipper, L. E., Somerfield, M. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00729 · Cited by 125
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Recent advances in targeted nanoparticles drug delivery to melanoma
Li, J., Wang, Y., Liang, R., An, X., Wang, K., Shen, G., Tu, Y., Zhu, J., & Tao, J. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.11.006 · Cited by 125
Self-citation
Metadata
- Authors
- Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O'Day, S. J., Sosman, J. A., Kirkwood, J. M., Eggermont, A. M. M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R. J., Flaherty, K. T., & McArthur, G. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Institut Gustave Roussy (FR)
- The Netherlands Cancer Institute (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Royal Marsden Hospital (GB)
- University of Zurich (CH)
- University of Tübingen (DE)
- European Institute of Oncology (IT)
- Tumour Institute of Tuscany (IT)
- University Health Network (CA)
- University of Manchester (GB)
- Hôpital Saint-André (FR)
- Essen University Hospital (DE)
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- Vanderbilt University (US)
- University of Pittsburgh (US)
- Plexxikon (United States) (US)
- Genentech (US)
- Massachusetts General Hospital (US)
- Peter MacCallum Cancer Centre (AU)
- ORCID
- Chapman, Paul B.
- Hauschild, Axel
- Robert, Caroline
- Haanen, John B.
- Ascierto, Paolo
- Larkin, James
- Dummer, Reinhard
- Garbe, Claus
- Testori, Alessandro
- Maio, Michele
- Hogg, David
- Lorigan, Paul
- Jouary, Thomas
- Schadendorf, Dirk
- Ribas, Antoni
- O'Day, Steven J.
- Sosman, Jeffrey A.
- Kirkwood, John M.
- Eggermont, Alexander M.M.
- Li, Jiang
- Hou, Jeannie
- Lee, Richard J.
- Flaherty, Keith T.
- McArthur, Grant A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-30
- Volume
- 364
- Issue
- 26
- Pages
- 2507-2516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3549296
- OpenAlex
- W2128542677
- Cited by
- 7,720
- References
- 28
- Citations by year
- 2026: 141 · 2025: 187 · 2024: 265 · 2023: 276 · 2022: 401 · 2021: 377 · 2020: 423 · 2019: 470 · 2018: 496 · 2017: 613 · 2016: 660 · 2015: 829 · 2014: 844 · 2013: 865 · 2012: 693
- FWCI
- 332.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institutes of Health (UL1TR000005)
- National Cancer Institute (K24CA097588)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, dacarbazine, metastatic melanoma, BRAF V600E mutation, BRAF inhibitors, overall survival, progression-free survival, drug toxicity, keratoacanthoma, photosensitivity
- MeSH terms
- Vemurafenib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Sulfonamides, Survival Analysis, Disease-Free Survival, Proto-Oncogene Proteins B-raf, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
